What the FDA labels say about taking them together
Cyclosporine and meloxicam
Meloxicam's FDA label (Qamzova) of July 16, 2026 names cyclosporine in its drug interactions section; cyclosporine's label does not name meloxicam itself but warns about its class (NSAIDs (nonsteroidal anti-inflammatory drugs)). The meloxicam label: “Concomitant use of XIFYRM and cyclosporine may increase cyclosporine’s nephrotoxicity.”
Check it at the source: the cyclosporine FDA label on DailyMed (effective August 10, 2026, Novartis Pharmaceuticals Corporation); the meloxicam FDA label on DailyMed (effective January 29, 2026, PD-Rx Pharmaceuticals, Inc.).
What does the cyclosporine label say about meloxicam?
Cyclosporine's label does not name meloxicam itself; it warns about its class (NSAIDs (nonsteroidal anti-inflammatory drugs)):
Cyclosporine label, drug interactionsIn addition, concomitant use of NSAIDs with cyclosporine, particularly in the setting of dehydration, may potentiate renal dysfunction.
Cyclosporine label, drug interactionsCyclosporine may reduce the clearance of digoxin, colchicine, prednisolone, HMG-CoA reductase inhibitors (statins), aliskiren, bosentan, dabigatran, repaglinide, NSAIDs, sirolimus, etoposide, and other drugs.
Source: FDA drug label (Neoral), Novartis Pharmaceuticals Corporation, effective August 10, 2026 (SPL set 94461af3-11f1-4670-95d4-2965b9538ae3), via openFDA; the full label on DailyMed
What does the meloxicam label say about cyclosporine?
Qamzova label (Nanjing Delova Biotech Co., Ltd., July 16, 2026), drug interactionsClinical Impact: Concomitant use of QAMZOVA and cyclosporine may increase cyclosporine’s nephrotoxicity. Intervention: During concomitant use of QAMZOVA and cyclosporine, monitor patients for signs of worsening renal function. NSAIDs and Salicylates
Source: FDA drug label (Qamzova, NDA217593), Nanjing Delova Biotech Co., Ltd., effective July 16, 2026 (SPL set 385fd779-1be1-49ae-8213-750b96ecc997), via openFDA
Source: FDA drug label (Xifyrm, NDA218395), Azurity Pharmaceuticals, Inc., effective June 18, 2025 (SPL set bf2b198c-0726-488a-b911-4fe394e4b56e), via openFDA
Source: FDA drug label (Meloxicam, NDA021530), Emerald Therapeutics, LLC, effective May 29, 2026 (SPL set 55af77dd-2abc-49a6-990c-399d5a5e7a91), via openFDA
Source: FDA drug label (MELOXICAM), PD-Rx Pharmaceuticals, Inc., effective January 29, 2026 (SPL set 19c13159-71f1-2427-e063-6394a90ad44e), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cyclosporine | Meloxicam | |
|---|---|---|
| Labeled for | Organ transplant rejection, Rheumatoid arthritis | Osteoarthritis, Rheumatoid arthritis, Pain |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $1.04 per unit 0.05% eye emulsion | $0.0166 per tablet 7.5 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once